JP2023509520A5 - - Google Patents
Info
- Publication number
- JP2023509520A5 JP2023509520A5 JP2022541894A JP2022541894A JP2023509520A5 JP 2023509520 A5 JP2023509520 A5 JP 2023509520A5 JP 2022541894 A JP2022541894 A JP 2022541894A JP 2022541894 A JP2022541894 A JP 2022541894A JP 2023509520 A5 JP2023509520 A5 JP 2023509520A5
- Authority
- JP
- Japan
- Prior art keywords
- pegcetacoplan
- subject
- level
- weeks
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958265P | 2020-01-07 | 2020-01-07 | |
| US62/958,265 | 2020-01-07 | ||
| US202062961032P | 2020-01-14 | 2020-01-14 | |
| US62/961,032 | 2020-01-14 | ||
| US202063038607P | 2020-06-12 | 2020-06-12 | |
| US63/038,607 | 2020-06-12 | ||
| US202063080648P | 2020-09-18 | 2020-09-18 | |
| US63/080,648 | 2020-09-18 | ||
| US202063124006P | 2020-12-10 | 2020-12-10 | |
| US63/124,006 | 2020-12-10 | ||
| PCT/US2021/012561 WO2021142171A1 (en) | 2020-01-07 | 2021-01-07 | Treatment of paroxysmal nocturnal hemoglobinuria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509520A JP2023509520A (ja) | 2023-03-08 |
| JP2023509520A5 true JP2023509520A5 (https=) | 2024-01-16 |
Family
ID=76788458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541894A Pending JP2023509520A (ja) | 2020-01-07 | 2021-01-07 | 発作性夜間ヘモグロビン尿症の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230076527A1 (https=) |
| EP (1) | EP4087541A4 (https=) |
| JP (1) | JP2023509520A (https=) |
| CN (1) | CN115243673A (https=) |
| AU (1) | AU2021206693A1 (https=) |
| CA (1) | CA3167017A1 (https=) |
| WO (1) | WO2021142171A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4398926A4 (en) * | 2021-09-09 | 2025-07-02 | Apellis Pharmaceuticals Inc | TREATMENT OF GEOGRAPHIC ATROPHY |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL269844B2 (en) * | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| WO2019118938A1 (en) * | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
-
2021
- 2021-01-07 CA CA3167017A patent/CA3167017A1/en active Pending
- 2021-01-07 US US17/791,194 patent/US20230076527A1/en active Pending
- 2021-01-07 EP EP21738676.2A patent/EP4087541A4/en active Pending
- 2021-01-07 WO PCT/US2021/012561 patent/WO2021142171A1/en not_active Ceased
- 2021-01-07 JP JP2022541894A patent/JP2023509520A/ja active Pending
- 2021-01-07 AU AU2021206693A patent/AU2021206693A1/en active Pending
- 2021-01-07 CN CN202180019150.5A patent/CN115243673A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verma et al. | Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. | |
| Taitelman et al. | Insulin in the management of the diabetic surgical patient: continuous intravenous infusion vs subcutaneous administration | |
| RU2733464C2 (ru) | Препараты tpp1 и способы лечения заболевания cln2 | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| CA2165822A1 (en) | The medical treatment using thyroid hormones | |
| JP2000514091A (ja) | 心筋症の処置 | |
| JP2015520188A5 (https=) | ||
| HRP20150438T1 (hr) | Uporaba lizosomalne kiselinske lipaze za lijeäśenje deficijencije lizosomalne kiselinske lipaze kod pacijenata | |
| CN112641771A (zh) | 用于治疗自身消化的组合物 | |
| WO2023231730A3 (zh) | 使用mazdutide的治疗方法 | |
| Godoy et al. | Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? | |
| JP2023509520A5 (https=) | ||
| Lombardo et al. | High‐dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration | |
| Drumheller et al. | Hemodynamic instability and abnormal vasopressor responsiveness in the setting of severe metabolic acidosis treated with adapted alkalinization and continuous renal replacement therapy in the emergency department | |
| Slomski | Vitamin D supplements don’t reduce COVID-19 risk | |
| AU2002220960A1 (en) | Regeneration of blood vessels | |
| WO2002045705A2 (en) | Regenaration of blood vessels | |
| Karatieieva et al. | Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes | |
| RU2106843C1 (ru) | Способ лечения близорукости | |
| Li et al. | The roller coaster of lamotrigine levels: Successful treatment of massive lamotrigine overdose with continuous veno-venous hemodiafiltration and rifampin | |
| EP3455894A2 (en) | Methods for treating hyperbilirubinemia with stannsoporfin and phototherapycross-reference to related applications | |
| Damasceno et al. | Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies | |
| Slomski | Trial Compares Glucose-Lowering Drugs for Type 2 Diabetes | |
| RU2192898C1 (ru) | Способ лечения герпетического кератита с изъязвлением | |
| Slomski | Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease |